Congress Already Impacting Industry Drug Pricing Abuses, Valeant Says
This article was originally published in The Pink Sheet Daily
Valeant investor, board member Ackman, outgoing CEO Pearson suggest congressional hearings have made a significant impression on biopharma industry.
You may also be interested in...
The third IL-17 inhibitor on the US market will have a $3,500/month list price. But in a crowded, safety-conscious space like psoriasis, it's unclear how low the discounted price will need to go and whether competitive pricing would be enough to sway prescribers.
Public Citizen reached out to the 28 largest biopharma manufacturers after Allergan announced its pricing pledge to see who else might follow suit. The answer was, not many.
US Senate Aging Committee wrapped up its investigation into price spikes for off-patent drugs with some relatively unsurprising (and – for most innovator companies – unthreatening) policy recommendations; a brief coda to the report offers two possible directions for future investigations: abuse of the patent system – or the impact of PBM practices.